Role of lncRNAs in the Development of an Aggressive Phenotype in Gallbladder Cancer

Abstract

Long non-coding RNAs are sequences longer than 200 nucleotides that are involved in different normal and abnormal biological processes exerting their effect on proliferation and differentiation, among other cell features. Functionally, lncRNAs can regulate gene expression within the cells by acting at transcriptional, post-transcriptional, translational, or post-translational levels. However, in pathological conditions such as cancer, the expression of these molecules is deregulated, becoming elements that can help in the acquisition of tumoral characteristics in the cells that trigger carcinogenesis and cancer progression. Specifically, in gallbladder cancer (GBC), recent publications have shown that lncRNAs participate in the acquisition of an aggressive phenotype in cancer cells, allowing them to acquire increased malignant capacities such as chemotherapy resistance or metastasis, inducing a worse survival in these patients. Furthermore, lncRNAs are useful as prognostic and diagnostic biomarkers since they have been shown to be differentially expressed in tumor tissues and serum of individuals with GBC. Therefore, this review will address different lncRNAs that could be promoting malignant phenotypic characteristics in GBC cells and lncRNAs that may be useful as markers due to their capability to predict a poor prognosis in GBC patients.

A comprehensive analysis of avian lymphoid leukosis-like lymphoma transcriptomes including identification of LncRNAs and the expression profiles

“…Emerging evidence showed that lncRNAs play important roles in a wide range of biological processes, including cancer development [68,69]. Previous studies reported that the expressions of lncRNAs have been altered in various types of human cancers and dysregulated lncRNAs' function as suppressors and oncogenes [70][71][72][73][74].…”

Clinical Advances in the Diagnosis and Treatment of Biliary Tract Diseases

“…As for adjuvant therapy, capecitabine is the standard of care in Western countries, while S-1 is the standard of care in Japan [ 13 ]. Genetic and molecular biological testing for personalized medicine [ 14 ] will become increasingly important in the future.…”